Licensed Practical Nurse in Bellbrook, OH Accepting Medicare
5 Licensed Practical Nurse nurses found. Showing 1 - 5
 Ms. Melissa Ann Yates, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3101 Mill Pond Dr, Bellbrook, OH 45305 Phone: 937-813-5790 |
Beth L. Hamilton, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3812 Callaway Ct, Bellbrook, OH 45305 Phone: 937-848-2081 |
Miss Inez Susie Coles, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1856 Surrey Trl Apt 7, Bellbrook, OH 45305 Phone: 937-782-8227 |
Lora Jean Bennett, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2365 Sullivan Dr, Bellbrook, OH 45305 Phone: 937-848-4167 Fax: 937-848-4167 |
Jennifer Lynn Burns, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 20 S East St, Bellbrook, OH 45305 Phone: 937-776-7186 |
News Archive
Non-alcoholic fatty liver disease linked to coronary artery disease
Because of the prevalence of obesity in our country, many Americans are expected to develop a serious condition called non-alcoholic fatty liver disease (NAFLD), which can lead to cirrhosis, fibrosis, and in some cases liver failure. It is also one of the best predictors for coronary artery disease.
Guardian launches global development website
The Guardian on Tuesday launched a new website that will cover global development issues, such as hunger and infant mortality, according to an introductory note on the site (Bunting, 9/14).
Afirma gene expression test can reduce unnecessary thyroid cancer surgeries
Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.
First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint
ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint.
Australia's medicines regulator close to decision on herceptin
Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.
› Verified 2 days ago